Helping patients breathe easier
Respiratory diseases comprise some of the leading causes of disability and death throughout the world. They include diseases that are very commonly known and prevalent including asthma, chronic obstructive pulmonary disease (COPD), pneumonia and lung cancer. They also include other serious and rare conditions such as hypereosinophilic syndrome, cystic fibrosis, and Interstitial pulmonary disease.
For all respiratory diseases, time is of the essence, because when you can’t effectively breathe, nothing else matters. Therefore, when it comes to advancing new therapies through clinical development to commercialization, Syneos Health is the CRO partner of choice.
A flexible, fully dedicated partner to ensure timely, quality delivery
Our Respiratory team represents many years of combined experience in respiratory clinical care, clinical development and commercialization. We work on a global scale, offering you clinical, regulatory and commercialization capabilities that extend from Europe and the Americas to Asia Pacific.
We are passionate about advancing science and accelerating new therapies across a broad spectrum of respiratory disease indications, including:
- Allergic rhinitis
- RSV infection
- Rare Diseases including interstitial lung disease
- Cystic fibrosis
Patients are our priority
Patients with respiratory illnesses have unique challenges inherent to their clinical trial participation. We understand these challenges and develop methodologies to reduce the overall patient trial participation burden. We also understand that these patients have high expectations for the value that new treatments can deliver.
We listen and learn from patients every day to understand their experience, recruit and enroll the right patients for the right studies, promote safety and informed decision-making, and enhance product value and access.
Ready to see what our Respiratory team can do for you?
Cross-functional collaboration is our hallmark
Many respiratory disorders involve newborns and children, or are rare diseases for which few or no treatments are currently available. These require further specialized expertise that is available from our Consortia in a number of key strategic areas, including Cell and Gene Therapy, Rare Disease and Pediatrics